The Chiron Approach to (3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-ol, a Key Subunit of HIV-1 Protease Inhibitor Drug, Darunavir.
Arun K GhoshShivaji B MarkadWilliam L RobinsonPublished in: The Journal of organic chemistry (2020)
We describe an enantioselective synthesis of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol which is a key subunit of darunavir, a widely used HIV-1 protease inhibitor drug for the treatment of HIV/AIDS patients. The synthesis was achieved in optically pure form utilizing commercially available sugar derivatives as the starting material. The key steps involve a highly stereoselective substrate-controlled hydrogenation, a Lewis acid catalyzed anomeric reduction of a 1,2-O-isopropylidene-protected glycofuranoside, and a Baeyer-Villiger oxidation of a tetrahydrofuranyl-2-aldehyde derivative. This optically active ligand alcohol was converted to darunavir efficiently.
Keyphrases
- hiv aids
- antiretroviral therapy
- hiv infected patients
- hiv infected
- human immunodeficiency virus
- hiv positive
- ejection fraction
- end stage renal disease
- hepatitis c virus
- hiv testing
- newly diagnosed
- prognostic factors
- hydrogen peroxide
- nitric oxide
- men who have sex with men
- adverse drug
- drug induced
- patient reported outcomes
- combination therapy
- electronic health record